Abstract #C165, Davis, DW et. al.,”Predictive Markers of Response in a Phase I/II Pharmacodynamic (PD) Study of Erlotinib and Bevacizumab for Recurrent or Metastatic Head and Neck Cancer (HNC)”.

Learn More